At Coho Biologics we specialize in RNA and protein biological testing, providing rapid testing solutions for the biotechnology and pharmaceutical industry.
Our mission is to empower researchers and developers with reliable, accurate, and high-quality analytical data, enabling the safe and effective advancement of new therapeutic candidates. Whether working with RNA-based treatments, monoclonal antibodies, protein therapeutics, and vaccine antigens, we are committed to supporting our clients during the development process, from preclinical research to early clinical trials.
Our team is composed of experienced biotechnology researchers with deep expertise in molecular biology, biochemistry, and analytical sciences. With decades of combined experience in the biotech industry, our scientists are uniquely equipped to address the complex challenges of product development. We bring a passion for innovation and a rigorous approach to scientific problem-solving, ensuring that our clients receive the most precise and actionable results.
We pride ourselves on maintaining high standards of quality and compliance. Operating under FDA regulatory guidelines, our laboratory adheres to cGMP and GLP standards, ensuring that all testing is conducted with the utmost accuracy and integrity. Our facilities are equipped with advanced technologies to perform a wide range of services, including storage, stability studies, potency assays, impurity characterization, and method development.
At Coho Biologics, we understand the critical importance of your work in improving human health. Our mission is to be a trusted partner, delivering exceptional service and personalized solutions to meet your specific needs. Together, we are committed to advancing the next generation of RNA and protein therapeutics and vaccines, shaping the future of medicine one breakthrough at a time.
Hannah Erickson, CEO
Darrick Carter, Ph.D.
Dr. Darrick Carter, Scientific Advisor, is a biochemist/biophysicist with over 20 years of biotechnology experience most recently serving as CSO of HDT Bio and VP of Adjuvant Technologies at AAHI (Formerly IDRI). He has founded five companies beginning with an internet startup. At Corixa he led a new tuberculosis vaccine into human trials. He started PAI as a bioinformatics company using proprietary artificial neural nets. He helped spin out Dharma Therapeutics a specialty pharma company for drug delivery. Next, he co-founded a company improving cancer outcomes, Compliment Corp. He is an inventor on over 120 patents and applications with more than 100 publications.
Sean Gray, Ph.D.
Dr. Gray is a biotech veteran with over 20 years experience in for-profit, non-profit, and government institutions. He has been awarded multiple NIH grants for the development of vaccines for intestinal and urinary schistosomiasis, and HIV. He oversaw the manufacture and release testing of Sm-p80 for SchistoShield™, the first ever human vaccine for schistosomiasis. This vaccine is currently in Phase 1b clinical trials in Africa. He is inventor/co-inventor on 5 patents or applications including a novel antigen for inclusion in a canine heartworm vaccine. He has co-authored more than 30 peer-reviewed publications and two book chapters.
Jenn Davis, M.T., C.L.S.
Geoff Holmes
Former Chairman and CEO of Time Warner Interactive and Founder of Blood Cell Storage Inc.
Institutional Biosafety Committee (IBC)
On behalf of the institution, IBCs review research involving recombinant or synthetic nucleic acid molecules for compliance with the NIH Guidelines.